Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin
- PMID: 19387877
- DOI: 10.1080/07357900802672738
Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin
Abstract
Background: To evaluate the effects of celecoxib, in combination with oxaliplatin, on tumour growth, cell apoptosis and angiogenesis in nude mice models.
Materials and methods: Xenograft mice model of colon cancer was established using the BALB/c nude mice. Medicine was administered respectively in different groups. Tumour volumes, the expression level of survivin, beta-catenin, VEGF mRNA level, the microvessel density and cell apoptosis were measured.
Results: Celecoxib, oxaliplatin and combination use caused a tumour inhibition of 35%, 31% and 63% respectively. Compared with control group, a significant redation of angiogenesis and the levels of COX-2, survivin and beta-cantenin protein, and increase of cell apoptosis were detected in tumors in celecoxib group. Celecoxib in combination with oxaliplatin could further promote cell apoptosis and reduce beta-catenin protein expression.
Conclusion: Celecoxib could inhibit tumor growth and enhance the antitumor effects of oxaliplatin through their synergistic role in inhibiting different targets.
Similar articles
-
Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.Exp Oncol. 2008 Mar;30(1):42-51. Exp Oncol. 2008. PMID: 18438340
-
Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.Biochem Pharmacol. 2005 Sep 1;70(5):658-67. doi: 10.1016/j.bcp.2005.05.028. Biochem Pharmacol. 2005. PMID: 16004971
-
Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.Cancer Lett. 2010 Feb 28;288(2):251-60. doi: 10.1016/j.canlet.2009.07.008. Epub 2009 Aug 6. Cancer Lett. 2010. PMID: 19664879
-
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.Expert Opin Investig Drugs. 2008 Feb;17(2):197-208. doi: 10.1517/13543784.17.2.197. Expert Opin Investig Drugs. 2008. PMID: 18230053 Review.
-
Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis.Int Immunopharmacol. 2009 Jun;9(6):701-15. doi: 10.1016/j.intimp.2009.02.003. Epub 2009 Feb 23. Int Immunopharmacol. 2009. PMID: 19239926 Review.
Cited by
-
Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling.J Toxicol Pathol. 2016 Oct;29(4):253-259. doi: 10.1293/tox.2016-0032. Epub 2016 Sep 21. J Toxicol Pathol. 2016. PMID: 27821910 Free PMC article.
-
The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through β-catenin-dependent and -independent mechanisms.Mol Cancer Res. 2010 Dec;8(12):1601-9. doi: 10.1158/1541-7786.MCR-10-0101. Epub 2010 Nov 11. Mol Cancer Res. 2010. PMID: 21071513 Free PMC article.
-
Celecoxib in breast cancer prevention and therapy.Cancer Manag Res. 2018 Oct 26;10:4653-4667. doi: 10.2147/CMAR.S178567. eCollection 2018. Cancer Manag Res. 2018. PMID: 30464589 Free PMC article. Review.
-
Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.Int J Mol Sci. 2011 Jan 18;12(1):668-81. doi: 10.3390/ijms12010668. Int J Mol Sci. 2011. PMID: 21340007 Free PMC article.
-
The Significant Influence of a Second Metal on the Antiproliferative Properties of the Complex [Ru(η6 -C10 H14 )(Cl2 )(dmoPTA)].Chemistry. 2022 Jan 13;28(3):e202103048. doi: 10.1002/chem.202103048. Epub 2021 Dec 8. Chemistry. 2022. PMID: 34806242 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous